The Critical Project Today

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/92071/1/j.1933-1592.2012.00594.x.pd

Toward a More Adequate Consequentialism

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142340/1/japp12302.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142340/2/japp12302_am.pd

SUBJECT-IVE AND OBJECTIVE

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72513/1/j.1467-9329.1995.tb00087.x.pd

Reply to Ralph Wedgwood

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43373/1/11098_2005_Article_2321.pd

Reply to Ben Eggleston

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43372/1/11098_2005_Article_2320.pd

Probability, explanation, and information

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43829/1/11229_2005_Article_BF01063889.pd

Cross-sectional study of the provision of interventional oncology services in the UK

Objective: To map out the current provision of interventional oncology (IO) services in the UK. Design: Cross-sectional multicentre study. Setting: All National Health Service (NHS) trusts in England and Scottish, Welsh and Northern Ireland health boards. Participants: Interventional radiology (IR) departments in all NHS trusts/health boards in the UK. Results: A total of 179 NHS trusts/health boards were contacted. We received a 100% response rate. Only 19 (11%) institutions had an IO lead. 144 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a recipient trust. 21 trusts (12%) had plans to provide an IO service or formal referral pathway in the next 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans to implement one. 70 trusts (39%) offered supportive and disease-modifying procedures. One trust had a formal referral pathway for supportive procedures. 73 trusts (41%) provided only supportive procedures (diagnostic or therapeutic). Of these, 43 (59%) had a referral pathway for disease-modifying IO procedures, either from a regional cancer network or through IR networks and 30 trusts (41%) did not have a referral pathway for disease-modifying procedures. Conclusion: The provision of IO services in the UK is promising; however, collaborative networks are necessary to ensure disease-modifying IO procedures are made accessible to all patients and to facilitate larger registry data for research with commissioning of new services